The Effect of Renal Failure on 18F-FDG Uptake: A Theoretic Assessment

This work addresses the issue of using 18F-FDG PET in patients with renal failure. Methods: A model analysis has been developed to compare tissue 18F-FDG uptake in a patient who has normal renal function with uptake in a theoretic limiting case that assumes tracer plasma decay is tracer physical decay and is trapped irreversibly. Results: This comparison has allowed us to propose, in the limiting case, that the usually injected activity be lowered by a factor of 3. We also proposed that the PET static acquisition be obtained at about 160 min after tracer injection. These 2 proposals were aimed at obtaining a similar patient radiation dose and similar tissue 18F-FDG uptake. Conclusion: In patients with arbitrary renal failure (i.e., between the 2 extremes of normal function and the theoretic limiting case), we propose that the injected activity be lowered (without exceeding a factor of 3) and that the acquisition be started between 45 and 160 min after tracer injection, depending on the severity of renal failure. Furthermore, the model also shows that the more severe the renal failure is, the more overestimated is the standardized uptake value, unless the renal failure indirectly impairs tissue sensitivity to insulin and hence glucose metabolism.

[1]  L M Hamberg,et al.  Simplified measurement of deoxyglucose utilization rate. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Y Yonekura,et al.  Noninvasive estimation of FDG input function for quantification of cerebral metabolic rate of glucose: optimization and multicenter evaluation. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Tomio Inoue,et al.  FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues , 2007, Annals of nuclear medicine.

[4]  Michèle Allard,et al.  A method to quantify the uptake rate of 2-[18F]fluoro-2-deoxy-D-glucose in tissues. , 2004, Nuclear medicine communications.

[5]  Marc Kachelriess,et al.  Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  A method to quantify at late imaging a release rate of 18F-FDG in tissues. , 2005, Comptes rendus biologies.

[7]  O B Paulson,et al.  No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. , 1999, Diabetes.

[8]  Sui Shen,et al.  MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan , 2009, Journal of Nuclear Medicine.

[9]  M. Hays,et al.  A mathematical model for the distribution of fluorodeoxyglucose in humans. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  R. DeFronzo,et al.  Insulin resistance in uremia. , 1981, The Journal of clinical investigation.

[11]  P. Marsden,et al.  The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. , 2002, Diabetes.

[12]  Hans-Jürgen Thiesen,et al.  18F-FDG kinetics and gene expression in giant cell tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Stephen R Thomas,et al.  MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.